Phase 2 N=102 Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=106 A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Schizophrenia
Primary: Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Total Score — -19.6; -16.5; -21.6 units on a scale
N/A N=126 Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis
Plaque Psoriasis
Primary: Change From Baseline in Psoriasis Assessment and Severity Index (PASI) Score at Week 24 — 21.02093; 20.40769; -18.40349; -15.64615 units on a scale
Phase 2 N=36 First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Multiple Myeloma
Primary: The Percent of Patients With Minimal Residual Disease (MRD) Status Changing to Negative at Day 100 (Post-AHCT), Among Patients With MRD Positive at the End of Induction…
Phase 3 N=464 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Neuroblastoma
Primary: Overall Survival (OS) Rates — 99.4; 93.5; 88.4 percentage of participants
Phase 2 N=30 Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
Renal Cell Carcinoma
Primary: Progression-free Survival — 8.3 months
Phase 2 N=671 Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old
Influenza
Primary: Ratios of Geometric Mean Titer (GMT) in Subjects (6 to <48 Months Old) After Receiving Two Doses of Either TIVc or TIVe Vaccine — 7.82; 5.5; 5.93; 3.69 Ratios
N/A N=31 The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity
Extracorporeal Membrane Oxygenation
Primary: ECMO Pump Longevity — 187; 131 hours — p=0.39
N/A N=21 Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
Renal Transplant Rejection
Primary: Radiologically Detectable Differences in Signal Intensity Between Healthy and Rejected Kidneys, Measured Using T2* Maps — 31.1; 23.3 ms (delayed postcontrast scans)
N/A N=49 Comparison of Two Programs for Weight Loss and Impact on Metabolic Syndrome
Metabolic Syndrome
Primary: Weight Loss — 1.6; 3.9 kg
N/A N=158 Patient Controlled Tissue Expansion for Breast Reconstruction
Breast Cancer
Primary: Successful Tissue Expansion and Exchange to a Permanent Breast Implant Unless Precluded by a Non-device Related Event — 149; 82 Breasts
N/A N=53 Multiple Treatment Study Using Low Field Magnetic Stimulation for Bipolar Depression
Bipolar Depression
Primary: Long Term Change: Montgomery-Åsberg Depression Rating Scale (MADRS) — -14.03; -9.75 units on a scale — p=<0.049
Phase 4 N=123 Early Diuresis Following Colorectal Surgery
Colorectal Disorders
Primary: Length of Hospital Stay — 99.6; 80.6 hours — p=0.564
N/A N=46 The EarLens Contact Hearing Device (CHD) Spectrum Study
Hearing Loss, Sensorineural
Primary: Change in Hearing Stability Using Unaided Air Conduction Thresholds. — -0.5 dB difference in Unaided Hearing
Phase 4 N=23 Mexiletine for the Treatment of Muscle Cramps in ALS
Muscle Cramps in Amyotrophic Lateral Sclerosis
Primary: Daily Muscle Cramps — 6.1; 4.7; 4.9; 2.5 Cramps per 24 hours